4.5 Article

Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCEP.119.007676

Keywords

atrial fibrillation; genetic variation; genetics; phenotype; pulmonary veins

Funding

  1. Swiss National Science Foundation [PP00P3_159322]
  2. Swiss Heart Foundation
  3. University of Basel
  4. Fonds de Recherche du Quebec-Sante (FRQS)
  5. McMaster University Department of Medicine Mid-Career Research Award
  6. Hamilton Health Sciences RFA Strategic Initiative Program
  7. National Institutes of Health (NIH) National Center for Research Resources for Case Western Reserve University [UL1RR024989]
  8. National Institutes of Health (NIH) Cleveland Clinic Clinical and Translational Science Award [UL1RR024989]
  9. Department of Cardiovascular Medicine Philanthropic Research Fund, Heart and Vascular Institute, Cleveland Clinic
  10. Tomsich Atrial Fibrillation Research Fund, Heart and Vascular Institute, Cleveland Clinic
  11. Center of Excellence in Cardiovascular Translational Functional Genomics of the Lerner Research, Cleveland Clinic
  12. Heart and Vascular Institutes, Cleveland Clinic
  13. Netherlands Heart Foundation [NHS2010B233]
  14. Center for Translational Molecular Medicine
  15. University Medical Center Groningen
  16. Netherlands Cardiovascular Research Initiative - Netherlands Heart Foundation
  17. Volkswagen Foundation Germany through the Lichtenberg professorship program [84901]
  18. Heart Center Leipzig
  19. Dell Loy Hansen Heart Foundation
  20. Robert E. Meyerhoff Professorship
  21. Dr Francis P. Chiaramonte Private Foundation
  22. Roz and Marvin Weiner Foundation
  23. Leducq Foundation
  24. Biosense Webster
  25. Siemens
  26. ImriCor
  27. National Institutes of Health [R01HL116280, R01-HL-142893, R01 HL090620, R01 HL111314]
  28. NIH [1R01HL139731]
  29. American Heart Association [18SFRN34250007, CRP7420009]
  30. German Federal Ministry of Education and Research (BMBF)
  31. European Commission's Horizon 2020 grant CATCH ME [GA 633196]
  32. St David's Medical Center
  33. NIH K23 grant [HL127704]
  34. CTSA from the National Center for Advancing Translational Sciences [UL1TR000445]

Ask authors/readers for more resources

Background: Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmia recurrence and repeat procedures are common. Studies examining surrogate markers of genetic susceptibility to AF, such as family history and individual AF susceptibility alleles, suggest these may be associated with recurrence outcomes. Accordingly, the aim of this study was to test the association between AF genetic susceptibility and recurrence after ablation using a comprehensive polygenic risk score for AF. Methods: Ten centers from the AF Genetics Consortium identified patients who had undergone de novo AF ablation. AF genetic susceptibility was measured using a previously described polygenic risk score (N=929 single-nucleotide polymorphisms) and tested for an association with clinical characteristics and time-to-recurrence with a 3 month blanking period. Recurrence was defined as >30 seconds of AF, atrial flutter, or atrial tachycardia. Multivariable analysis adjusted for age, sex, height, body mass index, persistent AF, hypertension, coronary disease, left atrial size, left ventricular ejection fraction, and year of ablation. Results: Four thousand two hundred seventy-six patients were eligible for analysis of baseline characteristics and 3259 for recurrence outcomes. The overall arrhythmia recurrence rate between 3 and 12 months was 44% (1443/3259). Patients with higher AF genetic susceptibility were younger (P<0.001) and had fewer clinical risk factors for AF (P=0.001). Persistent AF (hazard ratio [HR], 1.39 [95% CI, 1.22-1.58]; P<0.001), left atrial size (per cm: HR, 1.32 [95% CI, 1.19-1.46]; P<0.001), and left ventricular ejection fraction (per 10%: HR, 0.88 [95% CI, 0.80-0.97]; P=0.008) were associated with increased risk of recurrence. In univariate analysis, higher AF genetic susceptibility trended towards a higher risk of recurrence (HR, 1.08 [95% CI, 0.99-1.18]; P=0.07), which became less significant in multivariable analysis (HR, 1.06 [95% CI, 0.98-1.15]; P=0.13). Conclusions: Higher AF genetic susceptibility was associated with younger age and fewer clinical risk factors but not recurrence. Arrhythmia recurrence after AF ablation may represent a genetically different phenotype compared to AF susceptibility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available